Synapse - Works

Results (13087)

Treatment outcomes with purine nucleoside analog alone or with rituximab for hairy cell leukemia patients at first relapse: A multi-center outcomes analysis

Meeting Abstract

Hu, R.; Wei, W.; Gonter-Aubin, K.; Pinilla Ibarz, J.; Kabel, C. C.; Mato, A. R.; Madanat, Y. F.; Khajavian, S.; Shadman, M.; Hanlon, A.; more...
Blood (2019)

Fulltext@MSK | Save

Making progress in graft-versus-host disease prophylaxis and microbiome analysis in the Blood and Marrow Transplant Clinical Trials Network: Progress III (1703)/Mi-Immune (1801)

Meeting Abstract

Holtan, S.; Bhatt, A. S.; Fraser, R.; Perales, M. A.; Kean, L.; Saber, W.; Hamadani, M.; Logan, B. R.; Bolaños-Meade, J.
Blood (2019)

Fulltext@MSK | Save

Dose optimization of duvelisib in patients with relapsed or refractory peripheral T-cell lymphoma from the phase 2 PRIMO trial: Selection of regimen for the dose-expansion phase

Meeting Abstract

Horwitz, S. M.; Mehta-Shah, N.; Pro, B.; Jacobsen, E. D.; Casulo, C.; Brammer, J. E.; Haney, J.; Youssoufian, H.; Weaver, D. T.; Baglio, M.; more...
Blood (2019)

Fulltext@MSK | Save

Plasma cell myeloma residual disease quantitation using a next-generation sequencing-based IGH clonal rearrangement assay with the aid of a "spike-in" clonal sequence

Meeting Abstract

Ho, C.; Syed, M.; Yu, W.; Petrova-Drus, K.; Yao, J. J.; Moung, C.; Chang, J.; Benhamida, J.; Vanderbilt, C.; Roshal, M.; more...
Blood (2019)

Fulltext@MSK | Save

Pharmacodynamic effects and immune correlates of response to the CD20/cd3 bispecific antibody mosunetuzumab in relapsed or refractory non-Hodgkin lymphoma

Meeting Abstract

Hernandez, G.; Huw, L. Y.; Belousov, A.; Wilson, D.; Koeppen, H.; McCord, R.; Peng, K.; Bartlett, N. L.; Budde, L. E.; Assouline, S.; more...
Blood (2019)

Fulltext@MSK | Save

Monotherapy activity with the first CD20-targeted immunotoxin, MT-3724, in subjects with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL)

Meeting Abstract

Hamlin, P. A.; Musteata, V.; Zodelava, M.; Park, S. I.; Burnett, C.; Dabovic, K.; Williams, E. T.; Higgins, J. P.; Persky, D. O.
Blood (2019)

Fulltext@MSK | Save

Using current clinical markers to define high risk smoldering multiple myeloma: Agree to disagree

Meeting Abstract

Hill, E.; Korde, N.; Mailankody, S.; Morrison, C.; Dew, A.; Albert, J. H.; Graap, K.; Maura, F.; Landgren, O.; Kazandjian, D.
Blood (2019)

Fulltext@MSK | Save

Re-induction and targeted conditioning with anti-CD45 iodine ((131)I) apamistamab [Iomab-B] leads to high rates of transplantation and successful engraftment in older patients with active, relapsed or refractory (rel/ref) AML after failure of chemotherapy and targeted agents: Preliminary midpoint results from the prospective, randomized phase 3 Sierra Trial

Meeting Abstract

Gyurkocza, B.; Nath, R.; Stiff, P. J.; Agura, E.; Litzow, M.; Tomlinson, B.; Choe, H. K.; Abhyankar, S.; Seropian, S.; Chen, G. L.; more...
Blood (2019)

Fulltext@MSK | Save

Effect of active hepatitis C infection in relapse-free survival among patients with HIV-related diffuse large B-cell lymphoma

Meeting Abstract

Gonzalez-Lugo, J. D.; Acuna-Villaorduna, A.; Shah, U. A.; Friedman, E. W.
Blood (2019)

Fulltext@MSK | Save

Cardiovascular (CV)-related hospitalizations and associated costs among US patients in simplicity: An observational study of patients with chronic-phase chronic myeloid leukemia (CP-CML) in routine clinical practice

Meeting Abstract

Goldberg, S. L.; Mauro, M. J.; Cortes, J. E.; Keating, S. J.; Bhandari, H.; Chen, C.
Blood (2019)

Fulltext@MSK | Save